News and Insights
What Goes on in our Minds: Scientific Communication is Critical for Success in Commercializing Innovative Brain Health Therapies
August 7, 2026
The average human brain contains about 170 million cells1 comprising more than 3,000 specific cell types.2 Which is a short way of saying that, despite incredible progress in understanding how the brain functions in health and disease, we really don’t know what goes on in our minds. This complexity only increases in the context of innovating novel therapies for neurologic diseases, with multiple pathways and targets under evaluation in diverse clinical trials.
In fact, in Alzheimer’s disease alone, 17 different biological pathways and disease aspects are being explored to understand the cause of disease; ten approaches are being considered for diagnosis, assessment, and disease monitoring; and more than 18 different approaches to therapeutic intervention are being tested in human clinical trials.3 The landscape expands further when considering other neurologic diseases such as Parkinson’s disease, amyotrophic lateral sclerosis, and others.
Staying Top of Mind in a Crowded Landscape
As the scientific and medical communities push to understand what goes on in our minds, it’s our job to ensure that our clients are top of mind among investors, regulators, payers, and patients. In a crowded field, companies that can clearly differentiate themselves from competitors and establish cogent and compelling value propositions that resonate across diverse audiences will have the advantage.
Scientific communications is a foundation for achieving these critical goals across diverse audiences.
Investors need to understand competitive positioning, scientific rationale for the pathway/target/molecule, market potential, and regulatory risk. They also need to understand inflection points for value creation, as these play a critical role in decisions about when to invest.
Regulators will focus on risk-benefit profiles, especially for clinical trial data that includes novel endpoints (biomarkers, imaging technologies, wearable devices or sensors) and/or first in class therapeutic approaches. Educating regulators about the value and potential limitations of novel endpoints well in advance of filing for approval can help to reduce regulatory risk. Building support among the clinical and patient communities may also inform regulatory decisions.
Payers seek insights beyond safety and efficacy and base decisions on real-world evidence and health economics outcomes research (HEOR). Generating and communicating these data prior to commercialization can help optimize reimbursement and enable successful product launch without delay.
Patients prioritize understanding the potential risks and benefits of a particular therapy and how the therapy compares with other treatment options. Understanding and incorporating patient concerns and needs early in development is critical for commercializing therapies that patients believe have the potential to make a meaningful difference in their disease and quality of life. This may be especially true in neurologic diseases, which often carry fear and stigma.
Finding Peace of Mind in Scientific Communications
In the age of generative search, good data alone aren’t enough to guarantee success. Packaging your data into compelling narratives and formats that are optimized for detection by and inclusion in AI-based summaries is also essential. Ensuring your data is seen by the right audience in the appropriate context is as much an art today as it is a science. Working with a partner who has expertise in both scientific communications and the science of communicating in the AI era can give you the peace of mind you need to focus on advancing your brain health innovations.
_____________________________________________
1 Herculano-Houzel S. The remarkable, yet not extraordinary, human brain as a scaled-up primate brain and its associated cost. Proc Natl Acad Sci U S A. 2012 Jun 26;109 Suppl 1(Suppl 1):10661-8. doi: 10.1073/pnas.1201895109.
2 Brain Cell Census. Available at: https://www.science.org/collections/brain-cell-census.
3 Common Alzheimer’s and Related Dementias Research Ontology. Available at: https://iadrp.nia.nih.gov/about/cadro.
POSTED BY:
